This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Naturex ~ Glucevia™, Flowens™

SOUTH HACKENSACK, N.J.—Naturex introduced two new ingredients to its portfolio—Glucevia™, a patented natural extract of Fraxinus excelsior derived from seeds/fruits standardized to 10% Nuzhenide and GI3 that helps manage post-prandial glucose peaks in healthy people; and Flowens™, a full-spectrum cranberry-based ingredient for men’s health.


“Common ash (Fraxinus excelsior) has long been used by Mediterranean populations for its hypoglycemic effect, but until now few scientific studies had been conducted,” explained Elizabeth Bui, business unit director for nutrition & health. “Naturex was able to demonstrate the efficacy and safety of this extract on blood sugar control via in vitro, in vivo and 3 clinical studies."

This extract was tested in several clinical studies targeted at different populations. The latest one was a randomized, double blind, placebo-controlled, crossover clinical study in which overweight and mature volunteers received 1,000 mg/d of Glucevia for three weeks. The results showed post-prandial glycemia expressed as Area Under the Curve (AUC) was significantly reduced by 28.2 percent versus baseline.

Glucevia is able to work on all types of sugars both complex and simple. This is in contrast with other products available on the market. “We think Glucevia acts directly on the liver, helping it to stay healthy and better perform its daily functions,” said Bui. The liver plays a key role in glucose homeostasis and maintaining its health status is part of a strategy to manage blood sugar levels.

Naturex is launching Glucevia in the North American market during Supply Side West, which will be held in Las Vegas, on November 14 to 15. As a new ingredient within the NAT life™ range, it will be supported by in-depth technical documentation and marketing supports such as specific branding, a dedicated website and marketing campaign.


Flowens is supported by gold-standard clinical evidence illustrating its ability to improve Lower Urinary Tract Symptoms (LUTS) typically associated with Benign Prostatic Hyperplasia (BPH). More than 50 percent p of men in their fifties and 80 percent of men in their seventies suffer from BPH, resulting in a potential market of more than 26 million men in the United States alone. LUTS associated with BPH lead to deteriorating urinary conditions and a reduced quality of life as men age. Men are proactively seeking solutions to alleviate symptoms and improve their overall quality of life.

In a double blind, randomized, placebo-controlled intervention study, 250 mg/d or 500 mg/d of Flowens consumed showed statistically significant improvements in the key clinical marker for BPH/LUTS by up to 44 percent—the International Prostate Symptom Score (IPSS). Both doses also showed statistically significant improvements in uroflowmetry markers such as post-void residual volume (PRV) and bladder volume (VOL).

“The leading prostate nutritional supplement ingredient was the subject of a failed NCCAM (National Center for Complementary and Alternative Medicine) study and a negative Cochrane Review," said Dan Souza, sr. director of sales and marketing for NATUREX-DBS. "Flowens delivers clinical results without the unwanted sexual side effects commonly associated with pharmaceutical drugs and the current phytotherapy. It was also very well-received by participants in the study. More than 96 percent of the subjects who observed symptom improvements (frequency, urge incontinence, weak stream, urinary retention, etc.) would recommend Flowens to a friend."


comments powered by Disqus